SCARB1 and atherosclerosis: Although the induction of macrophage SR-BI together with an obviously unfavorable lipid composition of lipoproteins may in part explain the divergent effects of T-0681 on atherosclerosis development observed at different time-points, further studies are necessary to understand which mechanisms are responsible for the induction of the hepatobiliary sterol metabolism occurring between 4 and 8 weeks of treatment, making thyromimetics either pro- or anti-atherogenic.